ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan's Arkray opens door to treating diabetes with stem cells

OSAKA -- Japanese medical equipment maker Arkray has developed a system that automates the culturing of insulin-producing pancreatic cells derived from induced pluripotent stem cells, or iPS cells.

     The system needs tweaking in order to grow the cells in massive quantities, but the hope is that a version for research purposes will be ready within three years, offering a path to the treatment of diabetes by using regenerative medicine to restore the ability of the pancreas to secrete insulin.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more